

MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, January 19, 2017
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Bryan Larson, PharmD
Clinton Sheffield, MD
Clayton Grace, RPh
Jameson Rice, PharmD
Keith Tolman, MD

Elizabeth Young, PharmD
Susan Siegfried, MD
Abril Atherton, PharmD
Jake Jones, MD

Committee Members Excused:

None

Dept. of Health/Div. of Health Care Financing Staff Present:

Alyssa Pitts, RN
Merelynn Berrett, RN
Megan Schlappi, CPhT

Chad Hope, PharmD
Robyn Seely, PharmD
Heather Santacruz, RN

University of Utah Drug Regimen Review Center Staff Present:

Vicki Frydrych, PharmD

Other Individuals Present:

Ann Neilson, RD; ZS Pharma
Scott Black, OSI
Connor Willis, U of U
Cody Ball, Select Health
Michelle Bice, Gilead
Jeff Mussack, Ostuka
Eman Biltaji, U of U
Joseph Chang, U of U

Susan Parker, Bristol-Myers
Anne Van Beveren, Mallinkrodt
Jennifer Lauper, Bristol-Myers
Jeremy Christensen, DSAMH
Krystal Joy, Otsuka
Tony Rhodes, U of U
Valerie Gonzalez, UU COP
Kate Job, U of U

Meeting conducted by: Clinton Sheffield, MD

1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting and reminded everyone to sign in.
2. **Review and Approval of September Minutes:** Elizabeth Young made a motion to approve the minutes from November. Bryan Larson seconded the motion. All in favor with Keith Tolman abstaining.

3. **Revisit of citalopram from July 2016 Meeting:** Clinton Sheffield had expressed concern over the restricted status of citalopram 40mg. He discussed his concerns that the safety problems with citalopram are with doses “greater than” 40mg, not “greater than or equal to” 40mg. Bryan Larson mentioned that there are no quantity limits on lower doses of citalopram and is also subject to the DAW override. Abril Atherton provided data from recent studies addressing the safety and efficacy of citalopram at various doses and in comparison with other SSRIs. Clinton Sheffield made a motion that citalopram 40mg be considered equally safe and efficacious to the rest of the SSRI class. Clayton Grace seconded the motion. All in favor with Bryan Larson abstaining.
4. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss oral buprenorphine containing products. Updated Prior Authorization criteria were established for these agents.
5. **Opioid Combination Products:** Vicki Frydrych presented a review of Opioid Combination Products. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
6. **Public Comment:** N/A
7. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States’ Medicaid programs.
8. **Committee Discussion:**
 - a. Keith Tolman noted some of the problems with opioid combinations with acetaminophen. Clinton Sheffield pointed out that the greatest safety problems associated with opioids is not acetaminophen, but rather the opioids.
 - b. Susan Siegfried noted that agents containing butalbital or carisoprodol are problematic from a safety perspective.
 - c. Susan Siegfried made a motion that combination opioids containing butalbital or carisoprodol are less safe than other combination products with no added efficacy. Keith Tolman seconded the motion. Unanimous approval.
 - d. Jake Jones noted safety concerns with codeine containing products in pediatric patients; particularly in patients who are rapid metabolizers.
 - e. Keith Tolman made a motion that combination opioids containing caffeine be considered not equally safe and efficacious and made non-preferred on the PDL. Clinton Sheffield seconded the motion. Unanimous approval.
 - f. Clinton Sheffield made a motion that combination opioids containing acetaminophen, ibuprofen or aspirin be considered equally safe and efficacious for inclusion on the PDL. Keith Tolman seconded the motion. All in favor with Jake Jones abstaining.
 - g. Jake Jones made a motion to recommend that the DUR Board review codeine use in children; in particular children under 6 years of age. Clinton Sheffield seconded the motion. Unanimous approval.
 - h. Clinton Sheffield made a motion that at least one liquid opioid combination product be preferred. Keith Tolman seconded the motion. Unanimous approval.

9. **Meeting Adjourned:** Clinton Sheffield motioned to close the meeting. Keith Tolman seconded. Unanimous approval.

10. Next meeting is scheduled for February 16, 2017 (HIV NNRTIs, Integrase Inhibitors, and Entry Inhibitors).

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>